Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 1 4Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Peritoneal Neoplasms 1Hematologic Neoplasms 1

Interventions

Stem Cell Transplantation 3pertuzumab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Trastuzumab 2Cyclophosphamide 2trametinib 1thymoglobulin 1peginterferon alfa-2b 1orelabrutinib 1luspatercept 1kalinox 1dabrafenib 1atezolizumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tretinoin 1Standard of Care 1Practice Guidelines as Topic 1Patient Comfort 1Palliative Care 1Melphalan 1Immunotherapy, Adoptive 1Immunoglobulins 1Imipenem 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Ferric Oxide, Saccharated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hematologic Neoplasms × Practice Guidelines as Topic × Clear all
NCT03870750 2026-01-12

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Fred Hutchinson Cancer Center

Phase 2/3 Terminated
458 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡